Fair Money & Economic Opportunity

The Oncology Institute, Inc. (TOI.US) is a cancer care provider, not a financial institution.

The provided articles focus on general cancer information and research, not on TOI.US's business operations, financial products, or services. As such, there is no evidence in the articles to assess TOI.US against any of the KPIs related to fair money and economic opportunity, which are designed for companies involved in lending, insuring, moving, or storing money. Therefore, all KPIs are omitted due to a lack of relevant data.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While the company's supplier code of conduct includes prohibitions against forced labor and child labor, and mentions responsible minerals sourcing and efforts to ensure supplier compliance with its principles, these are policy statements and do not provide measurable data points such as percentages of certified spend, audit frequencies, number of incidents, traceability coverage, remediation speed, or the percentage of contracts with ethical clauses.

Therefore, all KPIs are omitted due to lack of concrete evidence.

No War, No Weapons

The Oncology Institute, Inc. (TOI) is a comprehensive cancer care provider operating in the United States. Its core business, as described in the articles, involves medical oncology, radiation oncology, hematology, and supportive care services. Financial reports detail revenue and expenses related to healthcare services.

There is no evidence in the provided articles to suggest that TOI derives any revenue from arms or defense contracts, develops dual-use technology, engages in sales to embargoed regimes, or has any exposure to controversial weapons. The company's operations are focused on civilian healthcare, and there is no indication of any involvement in military, defense, or conflict-related activities that would necessitate policies or oversight related to war or weapons.

Respect for Cultures & Communities

The company has at least three formal partnerships related to community engagement: one with Helios for clinical trials, one with The Fenway Institute for training materials, and one with the National LGBT Cancer Network.

The company uses the FRAME model as a foundation for documenting and reporting adaptation efforts for cultural relevance in training, which is a specific protocol for a cultural aspect, but not a general cultural impact assessment protocol for all operations. Formal grievance mechanisms are available for patients to voice complaints, with contact information provided for private health information and dispensary issues, but the coverage across all operational sites is not specified. Free, Prior and Informed Consent (FPIC) processes are not applicable to the company's operations. The company provides information both orally and in writing, and its cultural sensitivity training addresses using non-gendered terms, but a specific language inclusivity score is not provided. The company has a framework for responding to cultural incidents, where the Audit Committee investigates reports and determines disciplinary action. A total of 110 individuals completed cultural sensitivity training sessions, which included nurses, medical assistant staff, social workers, and physicians. This represents a portion of the company's workforce, which includes over 600 teammates and over 180 clinicians.

Safe & Smart Tech

The Oncology Institute (TOI.US) experienced a cybersecurity incident at a third-party software provider on November 3, 2025, which caused a brief, immaterial delay in fee-for-service collections.

No evidence of patient data exposure was identified. The company states it has not identified risks from known cybersecurity threats that have materially affected it. TOI.US adheres to HIPAA policy and the NIST Cybersecurity Framework for risk management. It conducts initial and annual HIPAA training for all staff with PHI access, and cybersecurity awareness training including hands-on exercises and simulations. The company uses encrypted electronic health records and computer firewalls. It also uses cloud service providers that ensure encryption and multi-factor authentication. Risk assessments include vulnerability scanning and penetration testing of critical systems, networks, and applications. The company emphasizes using only the minimum necessary protected health information (PHI) for specific purposes and has a minimum retention period of 7 years for medical records and 6 years for other documents. Patients have rights to access, amend, and restrict the use of their PHI, but TOI.US is not required to agree to all restriction requests. The company states it will not use or share information other than described in its privacy notice unless expressly agreed in writing. Quarterly reports on cybersecurity risks are provided to the Compliance Committee.

Zero Waste & Sustainable Products

TOI's partners demonstrate good hazardous waste management. GIC provides expert solutions for safe and compliant disposal of hazardous waste, including chemotherapy drugs and radioactive substances, adhering to strict regulations.

Daniels Health offers solutions for cytotoxic oncology waste disposal. TOI has had no waste disposal violations in the past 3 years. The company has company-wide waste reduction targets with timelines, and it has waste requirements for all tier-1 suppliers, prioritizing those with validated science-based targets. Daniels Health provides comprehensive customer education, including training, e-learning courses, and educational resources for staff on proper medical waste disposal. Additionally, Daniels' Chemosmart system eliminates disposable containers for cytotoxic waste, contributing to waste reduction.